You Should Look At The Stock Forecast For Amicus Therapeutics Inc. (NASDAQ: FOLD). – Marketing Sentinel
Home  »  Science   »  You Should Look At The Stock Forecast For Amicus T...

You Should Look At The Stock Forecast For Amicus Therapeutics Inc. (NASDAQ: FOLD).

In today’s recent session, 1.48 million shares of the Amicus Therapeutics Inc. (NASDAQ:FOLD) have been traded, and its beta is 1.20. Most recently the company’s share price was $10.17, and it changed around $0.29 or 2.94% from the last close, which brings the market valuation of the company to $2.48B. FOLD at last check was trading at a discount to its 52-week high of $12.63, offering almost -24.19% off that amount. The share price’s 52-week low was $5.91, which indicates that the recent value has risen by an impressive 41.89% since then. We note from Amicus Therapeutics Inc.’s average daily trading volume that its 3-month average coming to 3.88 million.

Amicus Therapeutics Inc. stock received a consensus recommendation rating of an Overweight, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 4 recommended FOLD as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Amicus Therapeutics Inc. is expected to report earnings per share of -$0.21 for the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Amicus Therapeutics Inc. (NASDAQ:FOLD) trade information

Instantly FOLD has been showing a green trend so far today with a performance of 2.94% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 10.25 on Tuesday, 06/21/22 increased the stock’s daily price by 0.78%. The company’s shares are currently down -14.46% year-to-date, but still up 25.38% over the last five days. On the other hand, Amicus Therapeutics Inc. (NASDAQ:FOLD) is 33.15% up in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $14.50, which translates to bulls needing to increase their stock price by 29.86% from its current value. Analyst projections state that FOLD is forecast to be at a low of $10.00 and a high of $20.00. In order for the stock price to hit the forecast high, the stock would need to plunge -96.66% from its current level, while the stock would need to crash 1.67% from its current level to reach the projected low.

Amicus Therapeutics Inc. (FOLD) estimates and forecasts

Amicus Therapeutics Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -8.86 percent over the past six months and at a 3.26% annual growth rate that is well above the industry average of 0.60%. The year-over-year growth rate is expected to be 16.90%, up from the previous year.

Consensus estimates provided by 11 financial analysts predict the company will bring in an average of $86.61 million in revenue for the current quarter. 11 analysts expect Amicus Therapeutics Inc. to make $91.33 million in revenue for the quarter ending Sep 2022. The company’s sales for the same quarters a year ago were $73.39 million and $79.55 million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 18.00%. Forecasts for the next quarter put sales growth at 14.80%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 9.10%.

FOLD Dividends

Amicus Therapeutics Inc.’s next quarterly earnings report is expected to be released around February 28 and March 04.

Amicus Therapeutics Inc. (NASDAQ:FOLD)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 1.05% of Amicus Therapeutics Inc. shares, and 109.70% of them are in the hands of institutional investors. The stock currently has a share float of 110.87%. Amicus Therapeutics Inc. stock is held by 322 institutions, with Wellington Management Group, LLP being the largest institutional investor. By Dec 30, 2021, it held 9.51% of the shares, which is about 26.65 million shares worth $307.79 million.

Perceptive Advisors Llc, with 9.48% or 26.56 million shares worth $306.76 million as of Dec 30, 2021, holds the second largest percentage of outstanding shares.

Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund were the top two Mutual Funds as of Dec 30, 2021. The former held 7.93 million shares worth $91.55 million, making up 2.83% of all outstanding shares. On the other hand, Vanguard Small-Cap Index Fund held roughly 7.0 million shares worth around $80.87 million, which represents about 2.50% of the total shares outstanding.

Leave a Comment

Your email address will not be published.

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]